A novel secondary ALK gene mutation which resistant to second-generation TKIs: a case report and literature review
The secondary mutation E803Q located in exon 14 seems resistant to most second-generation ALK-TKIs. If there is an opportunity, the efficacy of the third-generation ALK-TKI loratinib should be tested.
Authors
- Qiongxia Hu (ORCID: https://orcid.org/0000-0002-7707-4732)
- Lin Zhou (ORCID: https://orcid.org/0000-0002-6428-7392)
- Jia Liu (ORCID: https://orcid.org/0000-0002-2732-2718)
- Yingchun Gao
- Xiaqin Cheng
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-08-29
- DOI
- https://doi.org/10.3389/fonc.2024.1430350
- Citations
- 3
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.26